Skip to main content

2 Result(s)

within Article Remove this filter Susan O'Brien Remove this filter Science, Humanities and Social Sciences, multidisciplinary Remove this filter

and

  1. No Access

    Article

    A targeted treatment with off-target risks

    It emerges that blood-cancer-targeting drugs that block a tumour-survival pathway also activate a mutation-causing enzyme in mice and in human cells. This might have implications for the clinical use of these ...

    David A. Fruman, Susan O'Brien in Nature (2017)

  2. Article

    Open Access

    Clonal evolution in patients with chronic lymphocytic leukaemia develo** resistance to BTK inhibition

    Resistance to the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has been attributed solely to mutations in BTK and related pathway molecules. Using whole-exome and deep-targeted sequencing, we dissect evolut...

    Jan A. Burger, Dan A. Landau, Amaro Taylor-Weiner, Ivana Bozic… in Nature Communications (2016)

    Download PDF (1821 KB) View Article